Lana Janes

CEO, Abdera Therapeutics

Role: Associate

Sites: CDL-Oxford, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin

Streams: Advanced Therapies, Cancer

Lana Janes is a biopharmaceutical industry veteran with over 20 years of pharmaceutical development experience that spans the full life cycle of therapeutic product development. She is currently venture partner at adMare Biosciences where she is focused on identifying compelling areas of strategic commercial opportunity, and driving the creation and acceleration of new companies. She is also the CEO of Abdera Therapeutics, a precision oncology company co-founded in 2020 by adMare and Abcellera Biologics that is focused on the development of targeted radiotherapeutics for high unmet need cancers. Prior to that, she served as the senior vice president of intellectual property and technology development and chief patent officer at QLT Inc. (now Novelion Therapeutics Inc.) where she led all aspects of clinical development and IP strategy for the company’s therapeutic pipeline. Lana has also served as COO of Retinagenix Therapeutics (Seattle). Earlier in her career, she worked as a registered Canadian and U.S. patent agent at Ogilvy Renault LLP (now Norton Rose Fulbright), and at Roche Pharmaceuticals in Basel, CH, where she focused on the strategic IP and regulatory protection for therapeutic products. Lana is a received her bachelor’s in chemistry with honors from Harvard University and her PhD in biological organic chemistry from McGill University, where she also conducted post-doctoral work.